Literature DB >> 2386959

Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown.

V Mahadevan1, S T Malik, A Meager, W Fiers, G P Lewis, I R Hart.   

Abstract

Flavone acetic acid (FAA), a novel investigational antitumor agent, has been shown to cause early vascular shutdown in several experimental murine tumors, and this phenomenon is believed to be crucial to FAA's antitumor effects. However, the basis of this FAA-induced tumor vascular shutdown is unknown. In this study a radioactive tracer-clearance technique has been used as an objective indication of tumor blood flow to show that i.p. administered FAA induces a progressive and sustained reduction in blood flow in a colon 26 tumor growing s.c. in syngeneic mice. As early as 1 h after administration, there was a significant increase in the t1/2 clearance value for intratumorally injected 133Xe, reaching a peak at 3 h (117.3 +/- 36.4 versus 7.8 +/- 0.85 min for controls). Significant inhibition of blood flow was still apparent 48 h after a single injection of drug. This FAA-induced vascular shutdown was virtually abolished in tumor-bearing mice pretreated with an antiserum against tumor necrosis factor, while no such effect was observed in controls pretreated with nonimmune serum (t1/2 of 10.8 +/- 1.2 versus 65.6 +/- 8.0 min for controls). Furthermore, in vitro FAA was seen to induce tumor necrosis factor secretion from murine peritoneal cells and splenocytes. These studies suggest that FAA-induced tumor vascular shutdown in the colon 26 tumor is mediated by tumor necrosis factor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386959

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Vascular targeting agents.

Authors:  Mary Jo Pilat; Julie McCormick; Patricia Mucci LoRusso
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

3.  Bradykinin B1 and B2 receptors, tumour necrosis factor alpha and inflammatory hyperalgesia.

Authors:  S Poole; B B Lorenzetti; J M Cunha; F Q Cunha; S H Ferreira
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.

Authors:  D J Chaplin; G R Pettit; C S Parkins; S A Hill
Journal:  Br J Cancer Suppl       Date:  1996-07

5.  The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis.

Authors:  A C Issekutz; A Meager; I Otterness; T B Issekutz
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats.

Authors:  A M Karkar; Y Koshino; S J Cashman; A C Dash; J Bonnefoy; A Meager; A J Rees
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

8.  The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia.

Authors:  F Q Cunha; S Poole; B B Lorenzetti; S H Ferreira
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

9.  Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.

Authors:  L L Thomsen; B C Baguley; W R Wilson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.

Authors:  G J S Rustin; C Bradley; S Galbraith; M Stratford; P Loadman; S Waller; K Bellenger; L Gumbrell; L Folkes; G Halbert
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.